Advertisement
Advertisement

ASND

ASND logo

Ascendis Pharma A/S Ordinary Share

268.80
USD
Sponsored
-6.63
-2.41%
Jul 10, 12:26 UTC -4
Open

ASND Earnings Reports

Positive Surprise Ratio

ASND beat 16 of 42 last estimates.

38%

Next Report

Date of Next Report
Aug 05, 2026
Estimate for Q2 26 (Revenue/ EPS)
$338.61M
/
$1.37
Implied change from Q1 26 (Revenue/ EPS)
+37.31%
/
-277.92%
Implied change from Q2 25 (Revenue/ EPS)
+114.25%
/
-314.06%

Ascendis Pharma A/S Ordinary Share earnings per share and revenue

On May 07, 2026, ASND reported earnings of -0.77 USD per share (EPS) for Q1 26, missing the estimate of 0.20 USD, resulting in a -471.08% surprise. Revenue reached 246.60 million, compared to an expected 275.57 million, with a -10.51% difference. The market reacted with a +4.13% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 12 analysts forecast an EPS of 1.37 USD, with revenue projected to reach 338.61 million USD, implying an decrease of -277.92% EPS, and increase of 37.31% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Replimune Group, Inc.
Report Date
Jun 29, 2026 For Q4 26
Estimate
-$0.72
Actual
-$0.76
Surprise
-4.52%
logo
Beyond Air, Inc. Common Stock
Report Date
Jun 26, 2026 For Q4 26
Estimate
-$0.57
Actual
-$0.63
Surprise
-9.00%
FAQ
For Q1 2026, Ascendis Pharma A/S Ordinary Share reported EPS of -$0.77, missing estimates by -471.08%, and revenue of $246.60M, -10.51% below expectations.
The stock price moved up 4.13%, changed from $220.28 before the earnings release to $229.38 the day after.
The next earning report is scheduled for Aug 05, 2026.
Based on 12 analysts, Ascendis Pharma A/S Ordinary Share is expected to report EPS of $1.37 and revenue of $338.61M for Q2 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement